Announcements Trials
Browse Landscape

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 2Gastrointestinal 2Other solid neoplasm 1Other neoplasm 1Other hematologic neoplasm 1Dermatologic 1Breast 1

Conditions

Precancerous Conditions 1Melanoma 1Hepatitis C 1

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Ribavirin × Dermatologic × Clear all
NCT00897312 2016-04-25

Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

Vanderbilt-Ingram Cancer Center

Terminated
7 enrolled
DermatologicOther neoplasm

Hepatitis C, Melanoma, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡